Phagelux announces multiple agricultural commercial collaborations
By Canadian Poultry magazineNews Antimicrobial use Company News Global Market news Nutrition
Phagelux, Inc. a global biotechnology company focused on the development and commercialization of novel phage and lysin antibacterial products and solutions, made multiple announcements by entities within its agricultural division.
Tyler Homer, director of U.S. Operations for OmniLytics, a wholly owned subsidary of Phagelux, Inc., announced that OmniLytics has entered into a product development collaboration with NutriQuest to co-develop phage-based feed additive products.
Homer stated, “We are delighted to be working with one of the most innovative and fastest growing feed additive companies to create some truly unique and valuable new products.”
Steve Weiss, president for NutriQuest added, “This partnership couples the OmniLytics leadership position in creating phage-based solutions with our expertise in the feed additives business to create what we believe will be very important new solutions for poultry and livestock producers. Producers are losing access to valuable tools in poultry and livestock production that are resulting in increased costs and we believe the solutions we create together will fill those critical needs and provide a high level of value.”
Phagelux, Inc. has significant agricultural research, development and manufacturing capabilities in China.
William Wang, COO of Phagelux in China noted that Phagelux has added eleven new distributors to the Phagelux AgriHealth distribution network since January 1, 2018.
Wang noted that, “Although the line of our animal health products is still limited, and although we are just starting our sales efforts, the market seems to be responding positively to our products. In many agricultural categories treatments based on traditional antibiotics are either failing, or the public is demanding growers use less, and our products provide safe and natural alternatives that are often even more effective than traditional chemical antibiotics.”
Print this page